Top

Journal of Autism and Developmental Disorders

28-04-2024 | Original Article

Prescriptions for Antipsychotics: Youth with Intellectual/Developmental Disabilities Compared to Youth without Intellectual/Developmental Disabilities

Auteurs: Sandra Marquis, N. Esmé Marquis, Yona Lunsky, Kimberlyn M. McGrail, Jennifer Baumbusch

Gepubliceerd in: Journal of Autism and Developmental Disorders

Abstract

Purpose

The purpose of this study was to compare antipsychotic use by youth with intellectual/developmental disabilities to youth without IDD as they transitioned from pediatric to adult health care services. In addition, antipsychotic use was compared between youth with different types of IDD (autism, Fetal Alcohol Syndrome, Down syndrome and ‘other’).

Methods

Population level administrative health data was used to compare the dispensing of antipsychotics for youth aged 15 to 24 years with and without IDD, between 2010 and 2019. Because antipsychotics are associated with metabolic syndrome and type 2 diabetes, we also examined the dispensing data for metformin. In addition, we examined dispensed antipsychotics between different types of IDD. For both dispensing of antipsychotics and metformin, we used multi-variable logistic regression to derive adjusted odds ratios.

Results

There were 20,591 youth with IDD and 1,293,791 youth without IDD. Youth with IDD had significantly higher odds of being dispensed an antipsychotic (7.13 (6.82, 7.44)), even when a diagnosis of a psychotic illness was included in the regression. Higher odds were found in all age groups. Youth with IDD also had significantly higher odds of being dispensed metformin (3.739 (3.323, 4.208)) compared to youth without IDD. Youth with autism, FAS and ‘other’ types of IDD diagnoses all had higher odds of being dispensed an antipsychotic compared to youth with Down syndrome.

Conclusion

Compared to youth without IDD, youth with IDD were more frequently dispensed antipsychotics and metformin. These findings have important implications for the health of youth with IDD.

Alleen toegankelijk voor geautoriseerde gebruikers

Ark, T. K., Kesselring, S., Hills, B., & McGrail, K. M. (2020). Population Data BC: Supporting population data science in British Columbia. International Journal of Population Data Science, 4(2), 14. https://doi.org/10.23889/ijpds.v4i2.1133.CrossRef

ATC/DDD Index (2023). (2023). World Health Organization Centre for Drug Statistics Mehodology. https://www.whocc.no/atc_ddd_index/.

Axmon, A., Sandberg, M., Ahlströ, G., & Midlö, P. (2018). Fall-risk-increasing drugs and falls requiring health care among older people with intellectual disability in comparison with the general population: A register study. Plos One, 13(6), e0199218. https://doi.org/10.1371/journal.pone.0199218.CrossRefPubMedPubMedCentral

Bogart, K. R., & Dunn, D. S. (2019). Ableism Special issue introduction. Journal of Social Issues, 75(3), 650–664. https://doi.org/10.1111/josi.12354.CrossRef

Bowden, N., Thabrew, H., Kokaua, J., & Braund, R. (2020). National prescribing rates and polypharmacy for children and young people in New Zealand with and without autism spectrum disorder. Research in Autism Spectrum Disorders, 78, 101642. https://doi.org/10.1016/j.rasd.2020.101642.CrossRef

Bowring, D. L., Totsika, V., Hastings, R. P., Toogood, S., & McMahon, M. (2017). Prevalence of psychotropic medication use and association with challenging behaviour in adults with an intellectual disability. A total population study. Journal of Intellectual Disability Research, 61(6), 604–617. https://doi.org/10.1111/JIR.12359.CrossRefPubMed

Brylewski, J., & Duggan, L. (2004). Antipsychotic medication for challenging behaviour in people with learning disability. Cochrane Database of Systematic Reviews, 3. https://doi.org/10.1002/14651858.cd000377.pub2.

Caplan, B., Chlebowski, C., May, G., Baker-Ericzén, M. J., Connor, W., & Brookman-Frazee, L. (2022). Psychotropic medication use by children with autism served in publicly funded mental health settings. Journal of Developmental and Behavioral Pediatrics, 43(5), 252–261. https://doi.org/10.1097/DBP.0000000000001044.CrossRefPubMed

Challenging behaviour and learning disabilities: Prevention and interventions for people with learning disabilities whose behaviour challenges. (2015). National Institute for Health and Care Excellence (NICE Guidance); NICE. https://www.nice.org.uk/guidance/ng11/chapter/Recommendations#psychological-and-environmental-interventions.

Chokhawala, K., & Stevens, L. (2023, February 26). Antipsychotic medications. StatPearls; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK519503/.

Cvejic, R. C., & Trollor, J. N. (2018). Transition to adult mental health services for young people with an intellectual disability. Journal of Paediatrics and Child Health, 54(10), 1127–1130. https://doi.org/10.1111/jpc.14197.CrossRefPubMed

de Kuijper, G. M., & Hoekstra, P. J. (2017). Physicians’ reasons not to discontinue long-term used off-label antipsychotic drugs in people with intellectual disability. Journal of Intellectual Disability Research, 61(10), 899–908. https://doi.org/10.1111/JIR.12385.CrossRefPubMed

de Kuijper, G., Hoekstra, P., Visser, F., Scholte, F. A., Penning, C., & Evenhuis, H. (2010). Use of antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: Prevalence and reasons for prescription. Journal of Intellectual Disability Research, 54(7), 659–667. https://doi.org/10.1111/J.1365-2788.2010.01275.X.CrossRefPubMed

Downes, A., Anixt, J. S., Esbensen, A. J., Wiley, S., & Meinzen-Derr, J. (2015). Psychotropic medication use in children and adolescents with Down syndrome. Journal of Developmental and Behavioral Pediatrics, 36(8), 613–619. https://doi.org/10.1097/DBP.0000000000000179.CrossRefPubMed

Emerson, E., Totsika, V., Hatton, C., & Hastings, R. P. (2023). The mental health and wellbeing of adolescents with/without intellectual disability in the UK. Epidemiology and Psychiatric Services.

Esbensen, A. J., Greenberg, J. S., Seltzer, M. M., & Aman, M. G. (2009). A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. Journal of Autism and Developmental Disorders, 39, 1339–1349. https://doi.org/10.1007/s10803-009-0750-3.CrossRefPubMedPubMedCentral

Henderson, A., Mcskimming, P., Kinnear, D., Mccowan, C., Mcintosh, A., Allan, L., & Cooper, S. A. (2020). Changes over a decade in psychotropic prescribing for people with intellectual disabilities: Prospective cohort study. British Medical Journal Open, 10, e036862. https://doi.org/10.1136/bmjopen-2020-036862.CrossRef

Hirsch, L. E., & Pringsheim, T. (2016). Aripiprazole for autism spectrum disorders (ASD). In Cochrane Database of Systematic Reviews (Vol. 6, Issue CD009043). John Wiley and Sons Ltd. https://doi.org/10.1002/14651858.CD009043.PUB3.

Hsieh, K., Rimmer, J. H., & Heller, T. (2014). Obesity and associated factors in adults with intellectual disability. Journal of Intellectual Disability Research, 58(9), 851–863. https://doi.org/10.1111/jir.12100.CrossRefPubMed

Hudson, B. (2006). Making and missing connections: Learning disability services and the transition from adolescence to adulthood. Disability and Society, 21(1), 47–60. https://doi.org/10.1080/09687590500375366.CrossRef

Ip, A., Zwaigenbaum, L., & Brian, J. A. (2019). Post-diagnostic management and follow-up care for autism spectrum disorder. Paediatrics and Child Health, 461–468. https://doi.org/10.1093/pch/pxz121.

Libowitz, M. R., & Nurmi, E. L. (2021). The burden of antipsychotic-induced weight gain and metabolic syndrome in children. Frontiers in Psychiatry, 12, 623681. https://doi.org/10.3389/fpsyt.2021.623681.CrossRefPubMedPubMedCentral

Lin, E., Balogh, R., Cobigo, V., Ouellette-Kuntz, H., Wilton, A. S., & Lunsky, Y. (2013). Using administrative health data to identify individuals with intellectual and developmental disabilities: A comparison of algorithms. Journal of Intellectual Disability Research, 57(5), 462–477. https://doi.org/10.1111/jir.12002.CrossRefPubMed

Lord, C., Charman, T., Havdahl, A., Carbone, P., Anagnostou, E., Boyd, B., Carr, T., de Vries, P. J., Dissanayake, C., Divan, G., Freitag, C. M., Gotelli, M. M., Kasari, C., Knapp, M., Mundy, P., Plank, A., Scahill, L., Servili, C., Shattuck, P., & McCauley, J. B. (2021). The Lancet Commission on the future of care and clinical research in autism. The Lancet. https://doi.org/10.1016/S0140-6736(21)01541-5.CrossRefPubMed

Lord, C., Charman, T., Havdahl, A., Carbone, P., Anagnostou, E., Boyd, B., Carr, T., De Vries, P. J., Dissanayake, C., Divan, G., Freitag, C. M., Gotelli, M. M., Kasari, C., Knapp, M., Mundy, P., Plank, A., Scahill, L., Servili, C., Shattuck, P., & Mccauley, J. B. (2022). The Lancet Commission on the future of care and clinical research in autism. The Lancet, 399, 271–334. https://doi.org/10.1016/S0140-6736(21)01541-5.CrossRef

Loy, J. H., Merry, S. N., Hetrick, S. E., & Stasiak, K. (2017). Atypical antipsychotics for disruptive behaviour disorders in children and youths. The Cochrane Database of Systematic Reviews, 8(8), CD008559–CD008559. https://doi.org/10.1002/14651858.CD008559.PUB3.CrossRefPubMed

Lunsky, Y., Khuu, W., Tadrous, M., Vigod, S., Cobigo, V., & Gomes, T. (2017). Antipsychotic use with and without comorbid psychiatric diagnosis among adults with intellectual and developmental disabilities. Canadian Journal of Psychiatry, 63(6), 361–369. https://doi.org/10.1177/0706743717727240.CrossRefPubMedPubMedCentral

Mano-Sousa, B. J., Pedrosa, A. M., Alves, B. C., Galduróz, J. C. F., Belo, V. S., Chaves, V. E., & Duarte-Almeida, J. M. (2021). Effects of risperidone in autistic children and young adults: A systematic review and meta-analysis. Current Neuropharmacology, 19(4), 538–552. https://doi.org/10.2174/1570159x18666200529151741.CrossRefPubMedPubMedCentral

Marquis, S., Lunsky, Y., McGrail, K., & Baumbusch, J. (2024). Population level mental health diagnoses for youth with intellectual/developmental disabilities compared to youth without intellectual/developmental disabilities. Research on Child and Adolescent Psychopathology, 2–11. https://doi.org/10.1007/s10802-024-01174-0.

McLaren, J. L., Lichtenstein, J. D., Metcalfe, J. D., Charlot, L. R., Drake, R. E., & Beasley, J. B. (2021). Psychotropic use among youths with intellectual and developmental disabilities. Psychiatric Services, 72, 988–997. https://doi.org/10.1176/appi.ps.201900465.CrossRefPubMed

Nicol, G. E., Yingling, M. D., Flavin, K. S., Schweiger, J. A., Patterson, B. W., Schechtman, K. B., & Newcomer, J. W. (2018). Metabolic effects of antipsychotics on adiposity and insulin sensitivity in youths. A randomized clinical trial. JAMA Psychiatry, 75(8), 788–796. https://doi.org/10.1001/jamapsychiatry.2018.1088.CrossRefPubMedPubMedCentral

Niven, A., Goodey, R., Webb, A., & Shankar, R. (2018). The use of psychotropic medication for people with intellectual disabilities and behaviours that challenge in the context of a community multidisciplinary team approach. British Journal of Learning Disabilities, 46, 4–9. https://doi.org/10.1111/bld.12206.CrossRef

Nøttestad, J. A., & Linaker, O. M. (2003). Psychotropic drug use among people with intellectual disability before and after deinstitutionalization. Journal of Intellectual Disability Research, 47(6), 464–471. https://doi.org/10.1046/J.1365-2788.2003.00511.X.CrossRefPubMed

Ooi, A., Banno, B., McFee, K., Elbe, D., & Friedlander, R. (2023). Evaluating and managing irritability and aggression in children and adolescents with autism spectrum disorder: An algorithm. British Columbia Medical Journal, 65(8), 291–301.

Oyetoro, R., Wiemer, L., Bardhi, O., Louis, M., & Jacob, R. (2023). Special considerations for management of diabetes in adult patients with intellectual and developmental disabilities. Advances in Medicine. https://doi.org/10.1155/2023/2955772.CrossRefPubMedPubMedCentral

Park, S. Y., Cervesi, C., Galling, B., Molteni, S., Walyzada, F., Ameis, S. H., Gerhard, T., Olfson, M., & Correll, C. U. (2016). Antipsychotic use trends in youth with Autism Spectrum Disorder and/or intellectual disability: A meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 55(6), 456–468. www.jaacap.org.CrossRefPubMed

Rast, J. E., Tao, S., Schott, W., Shea, L. L., Brodkin, E. S., Kerns, C. M., Leonard, C. E., Murray, M. J., & Lee, B. K. (2023). Psychotropic medication use in children and youth with autism enrolled in Medicaid. Journal of Autism and Developmental Disorders. https://doi.org/10.1007/s10803-023-06182-5.CrossRefPubMed

Scheifes, A., Egberts, T. C. G., Stolker, J. J., Nijman, H. L. I., & Heerdink, E. R. (2016). Structured medication review to improve pharmacotherapy in people with intellectual disability and behavioural problems. Journal of Applied Research in Intellectual Disabilities, 29(4), 346–355. https://doi.org/10.1111/jar.12183. https://onlinelibrary-wiley-com.ezproxy.library.uvic.ca/doi/full/.CrossRefPubMed

Sheehan, R., Hassiotis, A., Walters, K., Osborn, D., Strydom, A., & Horsfall, L. (2015). Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK Population based cohort study. Bmj, 351, h4326. https://doi.org/10.1136/bmj.h4326.CrossRefPubMedPubMedCentral

Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Vseeman, M., Correll, C. U., & Carvalho, A. F. (2017). Safety, tolerability, and risks associated with first-and second-generation antipsychotics: A state-of-the-art clinical review. Therapeutics and Clinical Risk Management, 13, 757–777. https://doi.org/10.2147/TCRM.S117321.CrossRefPubMedPubMedCentral

Spady, D. W., Schopflocher, D. P., Svenson, L. W., & Thompson, A. H. (2001). Prevalence of mental disorders in children living in Alberta, Canada, as determined from physician billing data. Archives of Pediatrics & Adolescent Medicine, 155(10), 1153–1159. https://doi.org/10.1001/ARCHPEDI.155.10.1153.CrossRef

Statistical Analysis System Version 9.4. (n.d.). In SAS Institute Inc

Stopping over medication of people with a learning disability, autism or both (STOMP). (n.d.). Retrieved May 27, (2023). from https://www.england.nhs.uk/learning-disabilities/improving-health/stomp/.

Sullivan, W. F., Diepstra, H., Heng, J., Ally, S., Bradley, E., Casson, I., Hennen, B., Kelly, M., Korossy, M., McNeil, K., Abells, D., Amaria, K., Boyd, K., Gemmill, M., Grier, E., Kennie-Kaulbach, N., Ketchell, M., Ladouceur, J., Lepp, A., & Witherbee, S. (2018). Primary care of adults with intellectual and developmental disabilities: 2018 Canadian consensus guidelines. Canadian Family Physician, 64(4), 254–279. https://www.pmc.com/articles/PMC5897068.PubMedPubMedCentral

Tint, A., Brown, H. K., Chen, S., Lai, M. C., Tarasoff, L. A., Vigod, S. N., Parish, S., Havercamp, S. M., & Lunsky, Y. (2021). Health characteristics of reproductive-aged autistic women in Ontario: A population-based, cross-sectional study. Autism, 25(4), 1114–1124. https://doi.org/10.1177/1362361320982819.CrossRefPubMedPubMedCentral

van der Esch, C. C. L., Kloosterboer, S. M., van der Ende, J., Reichart, C. G., Kouijzer, M. E. J., De Kroon, M. M. J., van Daalen, E., Ester, W. A., Rieken, R., Dieleman, G. C., Hillegers, M. H. J., van Gelder, T., Koch, B. C. P., & Dierckx, B. (2021). Risk factors and pattern of weight gain in youths using antipsychotic drugs. European Child and Adolescent Psychiatry, 30, 1263–1271. https://doi.org/10.1007/s00787-020-01614-4.CrossRefPubMed

Wiggins, L. D., Nadler, C., Rosenberg, S., Moody, E., Reyes, N., Reynolds, A., Alexander, A., Daniels, J., Thomas, K., Giarelli, E., & Levy, S. E. (2021). Many young children with autism who use psychotropic medication do not receive behavior therapy: A multisite case-control study. The Journal of Pediatrics, 232, 264–271. https://doi.org/10.1016/j.jpeds.2021.01.043.CrossRefPubMedPubMedCentral

Young-Southward, G., Philo, C., & Cooper, S. A. (2017). What effect does transition have on health and well-being in young people with intellectual disabilities? A systematic review. Journal of Applied Research in Intellectual Disabilities, 30(5), 805–823. https://doi.org/10.1111/jar.12286.CrossRefPubMed

Titel: Prescriptions for Antipsychotics: Youth with Intellectual/Developmental Disabilities Compared to Youth without Intellectual/Developmental Disabilities
Auteurs: Sandra Marquis
N. Esmé Marquis
Yona Lunsky
Kimberlyn M. McGrail
Jennifer Baumbusch
Publicatiedatum: 28-04-2024
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-024-06344-z

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Purpose

Methods

Results

Conclusion

Log in om toegang te krijgen